Long noncoding RNA ANRIL as a novel biomarker in human cancer

References

• 1. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 81, 145–166 (2012).
  Medline CASGoogle Scholar
• 2. Djebali S, Davis CA, Merkel A et al. Landscape of transcription in human cells. Nature 489(7414), 101–108 (2012).
  Medline CASGoogle Scholar
• 3. Dong W, Ivan GB, Chris B et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474 (.7351), 390–394 (2011).
  MedlineGoogle Scholar
• 4. Ravasi T, Suzuki H, Pang KC et al. Experimental validation of the regulated expression of large numbers of non-coding RNAs from the mouse genome. Genome Res. 16(1), 11–19 (2006).
  Medline CASGoogle Scholar
• 5. Ip JY, Nakagawa S. Long non-coding RNAs in nuclear bodies. Dev. Growth Differ. 54(1), 44–54 (2012).
  Medline CASGoogle Scholar
• 6. He JH, Han ZP, Li YG. Association between long non-coding RNA and human rare diseases (review). Biomed. Rep. 2(1), 19–23 (2014).
  MedlineGoogle Scholar
• 7. Ernst C, Morton CC. Identification and function of long non-coding RNA. Front. Cell. Neurosci. 7, 168 (2013).
  MedlineGoogle Scholar
• 8. Ye N, Wang B, Quan ZF et al. Functional roles of long non-coding RNA in human breast cancer. Asian Pac. J. Cancer Prev. 15(15), 5993–5997 (2014).
  MedlineGoogle Scholar
• 9. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10(3), 155–159 (2009).
  Medline CASGoogle Scholar
• 10. Di FG, Capaccioli S, Lulli M. A pathophysiological view of the long non-coding RNA world. Oncotarget 5(22), 10976–10996 (2014).
  MedlineGoogle Scholar
• 11. Liang S, Luo HT, Qi L et al. Systematic study of human long intergenic non-coding RNAs and their impact on cancer. Science China Life Sciences 56(4), 324–334 (2013).
  MedlineGoogle Scholar
• 12. Kotake Y, Nakagawa T, Kitagawa K et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene 30 (.16), 1956–1962 (2011).
  Medline CASGoogle Scholar
• 13. Pasmant E, Laurendeau I, Héron D et al. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 67(8), 3963–3969 (2007).
  Medline CASGoogle Scholar
• 14. Holdt LM, Frank B, Markus S et al. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler. Thromb. Vasc. Biol. 30(3), 620–627 (2010).
  Medline CASGoogle Scholar
• 15. Li Z, Yu X, Shen J. ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers. Tumour Biol. 37(5), 5657–5661 (2016).
  Medline CASGoogle Scholar
• 16. Jarinova O, Stewart AR. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler. Thromb. Vasc. Biol. 29(10), 1671–1677 (2009).
  Medline CASGoogle Scholar
• 17. Holdt LM, Hoffmann S, Sass K et al. Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet. 9(7), e1003588 (2013).
  Medline CASGoogle Scholar
• 18. Lasse F, Theodosios K, Anuj G et al. Relationship between CAD risk genotype in the chromosome 9p21 locus and gene expression. Identification of eight new ANRIL splice variants. PLoS ONE 4(11), e7677 (2009).
  MedlineGoogle Scholar
• 19. Burd CE, Jeck WR, Liu Y et al. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet. 6(12), e1001233 (2010).
  MedlineGoogle Scholar
• 20. Sarkar D, Oghabian A, Bodiyabadu PK et al. Multiple isoforms of ANRIL in melanoma cells: structural complexity suggests variations in processing. Int. J. Mol. Sci. 18(7), 1378 (2017).
  Google Scholar
• 21. Thomas AA, Feng B, Chakrabarti S. ANRIL: a regulator of VEGF in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 58(1), 470–480 (2017).
  Medline CASGoogle Scholar
• 22. Kennison JA. The polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Annu. Rev. Genet. 29(1), 289–303 (1995).
  Medline CASGoogle Scholar
• 23. Müller J, Verrijzer P. Biochemical mechanisms of gene regulation by polycomb group protein complexes. Curr. Opin. Genet. Dev. 19(2), 150–158 (2009).
  Medline CASGoogle Scholar
• 24. Schuettengruber B, Chourrout D, Vervoort M et al. Genome regulation by polycomb and trithorax proteins. Cell 128(4), 735–745 (2007).
  Medline CASGoogle Scholar
• 25. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6(11), 846–856 (2006).
  Medline CASGoogle Scholar
• 26. Ringrose L, Paro R. Epigenetic regulation of cellular memory by the polycomb and trithorax group proteins. Annu. Rev. Genet. 38, 413–443 (2004).
  Medline CASGoogle Scholar
• 27. Margueron R, Li G, Sarma K et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32(4), 503–518 (2008).
  Medline CASGoogle Scholar
• 28. Shen X, Liu Y, Hsu YJ et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32(4), 491–502 (2008).
  Medline CASGoogle Scholar
• 29. Whitcomb SJ, Basu A, Allis CD et al. Polycomb group proteins: an evolutionary perspective. Trends Genet. 23(10), 494–502 (2007).
  Medline CASGoogle Scholar
• 30. Grossniklaus U, Paro R. Transcriptional silencing by polycomb-group proteins. Cold Spring Harb. Perspect. Biol. 6(11), a019331 (2014).
  MedlineGoogle Scholar
• 31. Jacobs JJ, Kieboom K, Marino S et al. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397(6715), 164–168 (1999).
  Medline CASGoogle Scholar
• 32. Itahana K, Zou Y, Itahana Y et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol. Cell. Biol. 23(1), 389–401 (2003).
  Medline CASGoogle Scholar
• 33. Bracken AP, Daniela KK, Nikolaj D et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21(5), 525–530(2007).
  Medline CASGoogle Scholar
• 34. Kotake Y, Cao R, Viatour P et al. pRB family proteins are required for H3K27 trimethylation and polycomb repression complexes binding to and silencing p16INK4a tumor suppressor gene. Genes Dev. 21(1), 49–54 (2007).
  Medline CASGoogle Scholar
• 35. Kia SK, Gorski MM, Giannakopoulos S et al. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol. Cell. Biol. 28(10), 3457–3464 (2008).
  Medline CASGoogle Scholar
• 36. Karl A, Cloos PAC, Lise R et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 23(10), 1171–1176 (2009).
  MedlineGoogle Scholar
• 37. Yap KL, Li S, Muñoz-Cabello AM et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol. Cell 38(5), 662–674 (2010).
  Medline CASGoogle Scholar
• 38. Francesca A, Ming-Ming Z, Walsh MJ. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res. 71(16), 5365–5369 (2011).
  MedlineGoogle Scholar
• 39. Harismendy O, Notani D, Song X et al. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature 470(7333), 264–268 (2011).
  Medline CASGoogle Scholar
• 40. Er-Bao Z, Rong K, Dan-Dan Y et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 5(8), 2276–2292 (2014).
  MedlineGoogle Scholar
• 41. Yan L, Sanoff HK, Hyunsoon C et al. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS ONE 4(4), e5027 (2009).
  MedlineGoogle Scholar
• 42. Cunnington MS, Santibanez Koref M, Mayosi BM et al. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet. 6(4), e1000899 (2010).
  MedlineGoogle Scholar
• 43. Broadbent HM, Peden JF, Lorkowski S et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum. Mol. Genet. 17(6), 806–814 (2008).
  Medline CASGoogle Scholar
• 44. Ada C, Kei K, Ryousuke O et al. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis 220(2), 449–455 (2012).
  MedlineGoogle Scholar
• 45. Zhang D, Sun G, Zhang H et al. Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K/Akt pathways. Biomed. Pharmacother. 85, 511–516 (2016).
  MedlineGoogle Scholar
• 46. Xu ST, Xu JH, Zheng ZR et al. Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer. Biomed. Pharmacother. 96(6), 14–21 (2017).
  MedlineGoogle Scholar
• 47. Chai L, Yuan Y, Chen C et al. The role of long non-coding RNA ANRIL in the carcinogenesis of oral cancer by targeting miR-125a. Biomed. Pharmacother. 103, 38–45 (2018).
  Medline CASGoogle Scholar
• 48. Liu P, Zhang M, Niu Q et al. Knockdown of long non-coding RNA ANRIL inhibits tumorigenesis in human gastric cancer cells via microRNA-99a-mediated down-regulation of BMI1. Braz. J. Med. Biol. Res. 51(10), e6839 (2018).
  MedlineGoogle Scholar
• 49. Zhao B, Yang Y, Hu LB et al. Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-β1/Smad signaling pathway. Cancer Biomark. 21(3), 613–620 (2018).
  Medline CASGoogle Scholar
• 50. Wang Y, Cheng N, Luo J. Downregulation of lncRNA ANRIL represses tumorigenicity and enhances cisplatin-induced cytotoxicity via regulating microRNA let-7a in nasopharyngeal carcinoma. J. Biochem. Mol. Toxicol. 31(7), e21904 (2017).
  Google Scholar
• 51. Hu X, Jiang H, Jiang X. Downregulation of lncRNA ANRIL inhibits proliferation, induces apoptosis, and enhances radiosensitivity in nasopharyngeal carcinoma cells through regulating miR-125a. Cancer Biol. Ther. 18(5), 331–338 (2017).
  Medline CASGoogle Scholar
• 52. Poi MJ, Li J, Sborov DW et al. Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Mol. Carcinog. 56(7), 1722–1732 (2017).
  Medline CASGoogle Scholar
• 53. Sun LY, Li XJ, Sun YM et al. LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of ADIPOR1/AMPK/SIRT1. Mol. Cancer 17(1), 127 (2018).
  MedlineGoogle Scholar
• 54. Royds JA, Pilbrow AP, Ahn A et al. The rs11515 polymorphism is more frequent and associated with aggressive breast tumors with increased ANRIL and decreased p16INK4a expression. Front. Oncol. 5, 306 (2016).
  MedlineGoogle Scholar
• 55. Hua L, Wang CY, Yao KH et al. High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 8(3), 3076–3082 (2015).
  Medline CASGoogle Scholar
• 56. Hoffmann MJ, Dehn J, Droop J et al. Truncated isoforms of lncRNA ANRIL are overexpressed in bladder cancer, but do not contribute to repression of INK4 tumor suppressors. Noncoding RNA 1(3), 266–284 (2015).
  MedlineGoogle Scholar
• 57. Qiu J, Wang Y, Liu Yl et al. The long non-coding RNA ANRIL promotes proliferation and cell cycle progression and inhibits apoptosis and senescence in epithelial ovarian cancer. Oncotarget 7(22), 32478–32492 (2016).
  MedlineGoogle Scholar
• 58. Johnson AD, Hwang SJ, Voorman A et al. Resequencing and clinical associations of the 9p21.3 region. A comprehensive investigation in the Framingham Heart Study. Circulation 127(7), 799–810 (2013).
  MedlineGoogle Scholar
• 59. Hungate EA, Vora SR, Gamazon ER et al. A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nat. Commun. 7, 10635 (2016).
  Medline CASGoogle Scholar
• 60. Ming C, An S, Li J. CDKN2B–AS may indirectly regulate coronary artery disease-associated genes via targeting miR-92a. Gene 629, 101–107 (2017).
  MedlineGoogle Scholar
• 61. Gong W, Peng J, Yin J et al. Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol. Sin. 38(4), 581–590 (2017).
  Medline CASGoogle Scholar
• 62. Teeuw WJ, Laine ML, Sergio B et al. A lead ANRIL polymorphism is associated with elevated CRP levels in periodontitis: a pilot case-control study. PLoS ONE 10(9), e0137335 (2015).
  MedlineGoogle Scholar
• 63. Frydenberg H, Thune I, Lofterød T et al. Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res. Treat. 155(2), 1–10 (2016).
  MedlineGoogle Scholar
• 64. Huang X, Zhang W, Shao Z. Association between long non-coding RNA polymorphisms and cancer risk: a meta-analysis. Biosci. Rep. 38(4), BSR20180365 (2018).
  Google Scholar
• 65. Chen S, Zhang JQ, Chen JZ et al. The over expression of long non-coding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: an in vivo and in vitro study. Int. J. Biol. Macromol. 102, 718–728 (2017).
  Medline CASGoogle Scholar
• 66. Zou ZW, Ma C, Medoro L et al. LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells. Oncotarget 7(38), 61741–61754 (2016).
  MedlineGoogle Scholar
• 67. Jin Y, Cui Z, Li X et al. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer. Oncotarget 8(16), 26090–26099 (2017).
  MedlineGoogle Scholar
• 68. Ratz L, Laible M, Kacprzyk LA et al. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells. Oncotarget 8(15), 25115–25130 (2017).
  MedlineGoogle Scholar
• 69. Hamidi A, Song J, Thakur N et al. TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α. Sci. Signal. 10(486), eaal4186 (2017).
  MedlineGoogle Scholar
• 70. Gil J, Peters G. Regulation of the INK4B–ARF–INK4A tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 7(9), 667–677 (2006).
  Medline CASGoogle Scholar
• 71. Sherr CJ. INK4-ARF locus in cancer and aging. Wiley Interdiscip. Rev. Dev. Biol. 1(5), 731–741 (2012).
  Medline CASGoogle Scholar
• 72. Kim WY, Sharpless NE. The regulation of INK4 / ARF in cancer and aging. Cell 127(2), 265–275 (2006).
  Medline CASGoogle Scholar
• 73. Moore L, Venkatachalam SH, Watt JC et al. Cooperativity of p19ARF, Mdm2 and p53 in murine tumorigenesis. Oncogene 22(49), 7831–7837 (2003).
  Medline CASGoogle Scholar
• 74. Popov N, Gil J. Epigenetic regulation of the INK4b-ARF-INK4a locus. Epigenetics 5(8), 685–690 (2010).
  Medline CASGoogle Scholar
• 75. Kotake Y, Naemura M, Murasaki C et al. Transcriptional regulation of the p16 tumor suppressor gene. Anticancer Res. 35(8), 4397–4401 (2015).
  Medline CASGoogle Scholar
• 76. Wen-Qing L, Pfeiffer RM, Hyland PL et al. Genetic polymorphisms in the 9p21 region associated with risk of multiple cancers. Carcinogenesis 35(12), 2698–2705 (2014).
  MedlineGoogle Scholar
• 77. Zhang H, Wang X, Chen X. Potential role of long non-coding RNA ANRIL in pediatric medulloblastoma through promotion on proliferation and migration by targeting miR-323. J. Cell. Biochem. 118(12), 4735–4744 (2017).
  Medline CASGoogle Scholar
• 78. Li Q, Tian Y, Hu G et al. Highly expressed antisense non-coding RNA in the INK4 locus promotes 5 growth and invasion of renal clear carcinoma cells via the β-catenin pathway. Oncol. Res. 25(8), 1373–1382 (2017).
  MedlineGoogle Scholar
• 79. Yin X, Liao Y, Xiong W, Zhang Y, Zhou Y, Yang Y. Hypoxia-induced lncRNAANRIL promotes cisplatin resistance in retinoblastoma cells through regulating ABCG2 expression. Clin. Exp. Pharmacol. Physiol.. 47(6), 1049–1057 (2020).
  Medline CASGoogle Scholar
• 80. Wai LT, Huck HN. Sox2: masterminding the root of cancer. Cancer Cell 26(1), 3–5 (2014).
  MedlineGoogle Scholar
• 81. Basu-Roy U, Bayin NS, Rattanakorn K et al. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nat. Commun. 6, 6411 (2015).
  Medline CASGoogle Scholar
• 82. Wu JH, Tang JM, Li J et al. Upregulation of SOX2-activated lncRNA ANRIL promotes nasopharyngeal carcinoma cell growth. Sci. Rep. 8(1), 3333 (2018).
  MedlineGoogle Scholar
• 83. Zhang JJ, Wang DD, Du CX et al. Long noncoding RNA ANRIL promotes cervical cancer development by acting as a sponge of miR-186. Oncol. Res. 26(3), 345–352 (2017).
  MedlineGoogle Scholar
• 84. Bi Q, Tang S, Xia L et al. Ectopic expression of miR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS ONE 7(6), e40169 (2012).
  Medline CASGoogle Scholar
• 85. Cortez MA, Nicoloso MS, Shimizu M et al. miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 49(11), 981–990 (2010).
  Medline CASGoogle Scholar
• 86. Ma J, Li T, Han X, Yuan H. Knockdown of lncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 144(2), 205–214 (2018).
  Medline CASGoogle Scholar
• 87. Dai W, Tian C, Jin S. Effect of lncRNA ANRIL silencing on anoikis and cell cycle in human glioma via microRNA-203a. Onco Targets Ther. 11, 5103–5109 (2018).
  Medline CASGoogle Scholar
• 88. Congrains A, Kamide K, Katsuya T et al. CVD-associated non-coding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC. Biochem. Biophys. Res. Commun. 419(4), 612–616 (2012).
  Medline CASGoogle Scholar
• 89. Wang J, Sun J, Wang J et al. Long noncoding RNAs in gastric cancer: functions and clinical applications. Onco Targets Ther. 9, 681–697 (2016).
  Medline CASGoogle Scholar
• 90. Ada C, Kei K, Mitsuru O et al. ANRIL: molecular mechanisms and implications in human health. Int. J. Mol. Sci. 14(1), 1278–1292 (2013).
  MedlineGoogle Scholar
• 91. Naemura M, Murasaki C, Inoue Y et al. Long noncoding RNA ANRIL regulates proliferation of non-small cell lung cancer and cervical cancer cells. Anticancer Res. 35(10), 5377–5382 (2015).
  Medline CASGoogle Scholar
• 92. Naemura M, Tsunoda T, Inoue Y et al. ANRIL regulates the proliferation of human colorectalcancer cells in both two- and three-dimensional culture. Mol.Cell. Biochem. 412 (.1–2), 141–146 (2015).
  MedlineGoogle Scholar
• 93. Furuta E, Okuda H, Kobayashi A et al. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim. Biophys. Acta 1805(2), 141–152 (2010).
  Medline CASGoogle Scholar
• 94. Jones NP, Schulze A, Targeting cancer metabolism – aiming at a tumour's sweet-spot. Drug Discov. Today 8 (.20), 232–241 (2003).
  Google Scholar
• 95. Fan C, Tang Y, Wang J et al. Role of long non-coding RNAs in glucose metabolism in cancer. Mol. Cancer 16(1), 130(2017).
  MedlineGoogle Scholar
• 96. Hu X, Bao J, Zhen W et al. The plasma lncRNA acting as fingerprint in non-small-cell lung cancer. Tumor Biol. 37(3), 3497–3504 (2016).
  Medline CASGoogle Scholar
• 97. Xie Y, Zhang Y. Du L et al. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Mol. Oncol. 12(5), 648–658 (2018).
  Medline CASGoogle Scholar
• 98. Wang M, Ma X, Zhu C et al. The prognostic value of long non coding RNAs in non small cell lung cancer: a meta-analysis. Oncotarget 7(49), 81292 (2016).
  MedlineGoogle Scholar
• 99. Lu Y, Zhou X, Xu L et al. Long noncoding RNA ANRIL could be transactivated by c-Myc and promote tumor progression of non-small-cell lung cancer. Onco Targets Ther. 9, 3077–3084 (2016).
  Medline CASGoogle Scholar
• 100. Sun Y, Zheng ZP, Li H et al. ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro. Mol. Med. Rep. 14(2), 1714–1720 (2016).
  Medline CASGoogle Scholar
• 101. Bahrami A, Hassanian SM, Khazaei M et al. The 9p21 locus as a potential therapeutic target and prognostic marker in colorectal cancer. Pharmacogenomics 19 (.5), 463 (2018).
  CASGoogle Scholar
• 102. Wang H, Liu Y, Zhong J et al. Long noncoding RNA ANRIL as a novel biomarker of lymph node metastasis and prognosis in human cancer: a meta-analysis. Oncotarget 9(18), 14608–14618 (2017).
  MedlineGoogle Scholar
• 103. Gao S, Zhao Z-Y, Wu R et al. Prognostic value of long noncoding RNAs in gastric cancer: a meta-analysis. Onco Targets Ther 11, 4877–4891 (2018).
  MedlineGoogle Scholar
• 104. Iranpour M, Soudyab M, Geranpayeh L et al. Expression analysis of four long noncoding RNAs in breast cancer. Tumor Biol. 37(3), 1–8 (2016).
  Google Scholar
• 105. Huang M-D, Chen W-M, Qi F-Z et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell proliferation by epigenetic silencing of KLF2. J. Hematol. Oncol. 8(1), 57 (2015).
  MedlineGoogle Scholar
• 106. Zhang B, Wang D, Ji TF et al. Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-κB signaling pathway in a rat model. Oncotarget 8(10), 17347–17359 (2017).
  MedlineGoogle Scholar
• 107. van der Pol E, Böing AN, Harrison P et al. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev. 64(3), 676–705 (2012).
  MedlineGoogle Scholar
• 108. Keller S, Sanderson MP, Stoeck A et al. Exosomes: from biogenesis and secretion to biological function. Immunol. Lett. 107(2), 102–108 (2006).
  Medline CASGoogle Scholar
• 109. Spaull R, McPherson B, Gialeli A et al. Exosomes populate the cerebrospinal fluid of preterm infants with post-haemorrhagic hydrocephalus. Int. J. Dev. Neurosci. 73, 59–65 (2019).
  Medline CASGoogle Scholar
• 110. Ostenfeld MS, Jeppesen DK, Laurberg JR et al. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res. 74(20), 5758–5771 (2014).
  Medline CASGoogle Scholar
• 111. Takahashi K, Yan IK, Kogure T et al. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio. 4(1), 458–467 (2014).
  Medline CASGoogle Scholar
• 112. Berrondo C, Flax J, Kucherov V et al. Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS ONE 11(1), e0147236(2016).
  MedlineGoogle Scholar
• 113. Krajčová A, Waldauf P, Anděl M et al. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit. Care 19, 398 (2015).
  MedlineGoogle Scholar
• 114. Chen F, Li M, Zhu X. Propofol suppresses proliferation and migration of papillary thyroid cancer cells by down-regulation of lncRNA ANRIL. Exp. Mol. Pathol. 107, 68–76 (2019).
  Medline CASGoogle Scholar
• 115. Xu S, Wang H, Pan H. ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma. Cancer Lett. 381(1), 41–48 (2016).
  Medline CASGoogle Scholar
• 116. Ge J, Geng S, Jiang H. Long noncoding RNAs antisense noncoding RNA in the INK4 locus (ANRIL) correlates with lower acute exacerbation risk, decreased inflammatory cytokines, and mild GOLD stage in patients with chronic obstructive pulmonary disease. J. Clin. Lab. Anal. 33(2), e22678 (2019).
  MedlineGoogle Scholar
• 117. Hu J, Wang D, Wu H. Long non-coding RNA ANRIL-mediated inflammation response is involved in protective effect of rhein in uric acid nephropathy rats. Cell Biosci. 9, 11 (2019).
  MedlineGoogle Scholar
• 118. Lee J, Jung JH, Chae YS et al. Long noncoding RNA snaR regulates proliferation, migration and invasion of triple-negative breast cancer cells. Anticancer Res. 36 (.12), 6289 (2016).
  Medline CASGoogle Scholar
• 119. Lan WG, Xu DH, Xu C et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol. Rep. 36(1), 263 (2016).
  Medline CASGoogle Scholar
• 120. Liu B, Shen E-D, Liao M-M et al. Expression and mechanisms of long non-coding RNA genes MEG3 and ANRIL in gallbladder cancer. Tumor Biol. 37 (.7), 9875–9886 (2016).
  Medline CASGoogle Scholar